HC
TVTX icon

Henshaw Capital’s Travere Therapeutics TVTX Stock Holding History

Henshaw Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,618
Closed -$660K – 263
2025
Q3 		$660K Sell
27,618
-6,749
-20% -$127K 0.02% 145
2025
Q2 		$509K Hold
34,367
– – 0.02% 230
2025
Q1 		$616K Buy
34,367
+5,194
+18% +$105K 0.03% 201
2024
Q4 		$508K Hold
29,173
– – 0.02% 216
2024
Q3 		$408K Hold
29,173
– – 0.02% 250
2024
Q2 		$240K Hold
29,173
– – 0.01% 271
2024
Q1 		$225K Hold
29,173
– – 0.01% 272
2023
Q4 		$262K Hold
29,173
– – 0.01% 256
2023
Q3 		$261K Buy
29,173
+12,686
+77% +$179K 0.02% 243
2023
Q2 		$253K Hold
16,487
– – 0.01% 207
2023
Q1 		$371K Hold
16,487
– – 0.02% 155
2022
Q4 		$347K Buy
16,487
+1,989
+14% +$42.1K 0.02% 158
2022
Q3 		$357K Sell
14,498
-1,734
-11% -$44.8K 0.03% 178
2022
Q2 		$393K Hold
16,232
– – 0.03% 169
2022
Q1 		$418K Sell
16,232
-1,374
-8% -$36.5K 0.02% 185
2021
Q4 		$546K Hold
17,606
– – 0.03% 163
2021
Q3 		$427K Hold
17,606
– – 0.03% 184
2021
Q2 		$257K Buy
17,606
+4,573
+35% +$90.2K 0.02% 310
2021
Q1 		$325K Buy
13,033
+327
+3% +$9.04K 0.02% 250
2020
Q4 		$346K Sell
12,706
-2,497
-16% -$58.3K 0.03% 223
2020
Q3 		$281K Hold
15,203
– – 0.02% 239
2020
Q2 		$310K Hold
15,203
– – 0.03% 210
2020
Q1 		$222K Buy
+15,203
New +$229K 0.02% 237
2019
Q2 		– Sell
-9,136
Closed -$207K – 305
2019
Q1 		$207K Buy
9,136
+182
+2% +$4.02K 0.02% 268
2018
Q4 		$203K Buy
+8,954
New +$223K 0.02% 253

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Henshaw Capital's TVTX Position: Q4 2025 in Review

Henshaw Capital sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 27,618 shares — an estimated $660K sold.

Henshaw Capital first reported a position in TVTX in Q4 2018 and held it in 25 quarters. The position peaked at $660K in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Henshaw Capital reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Henshaw Capital sold 27,618 Travere Therapeutics shares in Q4 2025, an estimated $660K.
  • Henshaw Capital first reported a position in Travere Therapeutics in Q4 2018 and held it in 25 quarters.
  • Henshaw Capital's Travere Therapeutics position peaked at $660K in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Henshaw Capital's 13F filing for Q4 2025, filed 28 May 2026.